Recombinant Human CD109 protein (rFc Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human CD109 protein (rFc Tag) (Eg2673)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2673

---

Validation Data Gallery

• 

  Purity of Recombinant Human CD109 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human CD109 protein Val22-Ser1268 (Accession# Q6YHK3-1, Tyr703Ser and Tyr1241Met) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 135228
• Accession: Q6YHK3-1
• PredictedSize: 165.2 kDa
• SDS-PAGE: 135-220 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CD109, also named as CPAMD7, is a member of the alpha2-macroglobulin/complement superfamily and is preferentially expressed on hematopoietic stem as well as progenitor cell subsets. It is a glycosylphosphatidylinositol (GPI)-anchored protein, first identified as a marker for activated T cells and platelets. CD109 stands out as the most potent negative regulator of canonical TGF-β signaling and responses. Additionally, CD109 might be a useful molecular target for the development of new therapeutics for malignant tumors, such as squamous cell carcinoma.

References:

1. Lin, Martin et al. Blood vol. 99,5 (2002): 1683-91.
2. Murray, L J et al. Experimental hematology vol. 27,8 (1999): 1282-94.
3. Sutherland, D R et al. Blood vol. 77,1 (1991): 84-93.
4. Tam, B Y et al. Journal of cellular biochemistry vol. 70,4 (1998): 573-86.
5. Tam, B Y et al. Journal of cellular biochemistry vol. 83,3 (2001): 494-507.
6. Hashimoto, Mizuo et al. Oncogene vol. 23,20 (2004): 3716-20.